Bayer launches Yaz in Europe; Teva sues Sandoz over Copaxone;

> Bayer is launching its low-dose contraceptive pill Yaz in Europe this month, the company said. Bayer Release

> Teva Pharmaceutical Industries has sued Sandoz, the generic subsidiary of Novartis, and Momenta for allegedly infringing the patents on the multiple sclerosis drug Copaxone. Report

> SAFC Pharma, a pharmaceutical products subsidiary of Sigma-Aldrich Corp., has announced plans for a $30 million expansion of its Madison, Wisc., operations. Report

> Ortho Biotech announced the European Commission's approval of Velcade for some patients with previously untreated multiple myeloma, in combination with melphalan and prednisone. Ortho Release

> India's Aurobindo Pharms received tentative FDA approval to manufacture and market Abacavir Sulfate, its version of GlaxoSmithKline's HIV treatment Lamivudine. Report

> Alembic, India's oldest pharmaceutical company, is planning to double its turnover in the next two to three years by foraying into the regulated markets of the US and Europe as well as contract manufacturing, a company director said. Report

> Perrigo said it acquired the exclusive U.S. rights to sell and distribute levocetirizine tablets, the generic version of UCB's Xyzal tablets, from Synthon Pharmaceuticals Inc. Report

> Biovail got Canadian regulators' nod for an expanded indication for once-daily Ralivia to include the treatment of moderately severe pain in addition to moderate pain. Report

> Philanthropists Eli and Edythe Broad announced plans to donate a massive $400 million for genetic research at the Broad Institute. Report

> The FDA is taking a critical look at Pfizer and Ligand's Fablyn, an osteoporosis drug the companies developed together that has been submitted to the FDA. Report

> With a $500 million investment, Brno--the second-largest city in the Czech Republic--hopes to appeal to the biotech sector and establish a reputation as a major European research hub. Report

> Abraxis has signed a $295M licensing deal with ProMetic Life Sciences to develop and market four biotech drugs. Report

> BIO--the industry's trade organization--isn't supporting a particular candidate in this coming election. Why? Because no matter who wins, the industry can look forward to a level of support it hasn't experienced in the last eight years. Report

Emerging Drug Developer: Acucela

And Finally... People who sweat heavily during exercise are less likely to develop asthma, a new study shows. Report

Suggested Articles

More than a year after J&J and Bayer pulled the plug on Xarelto in patients after a rare valve replacement, the pair are still seeking answers.

Novartis hopes to leverage its existing presence in the hematology community to achieve a successful launch of Adakveo.

AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics looks particularly strong.